Mostrar el registro sencillo del ítem

Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation

dc.rights.licenseopenen_US
dc.contributor.authorBLIN, Patrick
dc.contributor.authorDUREAU-POURNIN, C.
dc.contributor.authorCOTTIN, Y.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBENICHOU, Jacques
dc.contributor.authorMISMETTI, P.
dc.contributor.authorABOUELFATH, A.
dc.contributor.authorLASSALLE, Regis
dc.contributor.authorDROZ, C.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOORE, Nicholas
dc.date.accessioned2020-05-19T08:32:55Z
dc.date.available2020-05-19T08:32:55Z
dc.date.issued2019
dc.identifier.issn1365-2125 (Electronic) 0306-5251 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/7635
dc.description.abstractEnBACKGROUND: We compared the 1-year safety and effectiveness of dabigatran 110 mg (D110) or 150 mg (D150) to vitamin K antagonists (VKA) in patients with non-valvular atrial fibrillation (NVAF), METHODS: New user cohort study of patients dispensed D110 or D150 vs. VKA in 2013 for NVAF, followed 1 year in the French Systeme National des Donnees de Sante (SNDS, 66 million persons). D110 and D150 users were matched 1:1 with VKA users on sex, age, date of first drug dispensing, and high-dimensional propensity score (hdPS). Hazard ratios (HR [95% confidence intervals]) for stroke and systemic embolism (SSE), major bleeding (MB), and death were computed using Cox proportional hazards or Fine and Gray models during exposure. RESULTS: In 14,442 matched D110 and VKA patients, mean age 79, 49% male, 91% with CHA2 DS2 -VASc >/=2 and 8% with HAS-BLED >3, incidence rates of SSE were 1.9% and 2.6% person-years (HR 0.69 [0.56-0.84]), MB 1.8% and 2.9% (0.62 [0.51-0.76]), death 7.2% and 8.6% (0.84 [0.76-0.94]). In 8,389 matched D150 and VKA patients, mean age 67, 67% male, 65% with CHA2 DS2 -VASC >/= 2; < 5% HAS-BLED > 3, incidence rates were for SSE 1.4% and 1.9% (0.76 [0.56-1.04]), MB 0.6 % and 1.9% (0.30 [0.20-0.46]), death 1.6% and 3.6% (0.46 [0.35-0.59]). Numbers needed to treat to observe one fewer death were 78 for D110, 88 for D150 CONCLUSION: In real life D110 and D150 were at least as effective and safer than VKA.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enEffectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation
dc.title.alternativeBr J Clin Pharmacolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/bcp.13815en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30423205en_US
bordeaux.journalBritish Journal of Clinical Pharmacologyen_US
bordeaux.page432-441en_US
bordeaux.volume85en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03209505
hal.version1
hal.date.transferred2021-04-27T09:35:47Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=British%20Journal%20of%20Clinical%20Pharmacology&amp;rft.date=2019&amp;rft.volume=85&amp;rft.issue=2&amp;rft.spage=432-441&amp;rft.epage=432-441&amp;rft.eissn=1365-2125%20(Electronic)%200306-5251%20(Linking)&amp;rft.issn=1365-2125%20(Electronic)%200306-5251%20(Linking)&amp;rft.au=BLIN,%20Patrick&amp;DUREAU-POURNIN,%20C.&amp;COTTIN,%20Y.&amp;BENICHOU,%20Jacques&amp;MISMETTI,%20P.&amp;rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem